FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug Daraxonrasib MedNews
Today, the U.S. Food and Drug Administration is announcing that it issued a safe to proceed letter to Revolution Medicines, allowing the sponsor to initiate an